TRVI

Over the past six months, Trevi Therapeutics' stock price has experienced notable movements, increasing by 70.72% from $8.47 to $14.46 per share between September 24, 2025, and September 23, 2026, though it recently traded around $13.42 as of October 7, 2026, down approximately 8% over the preceding week. Key events impacting the stock include the release of positive results from its Phase 2b CORAL trial for IPF-related chronic cough and its Phase 2a RIVER trial for refractory chronic cough. The company completed a follow-on common stock offering in the first quarter of 2026, generating approximately $162 million in net proceeds, which is expected to extend its cash runway into 2030. Following an End-of-Phase 2 meeting with the FDA, Trevi Therapeutics gained alignment on its clinical development plan for IPF-related chronic cough and is on track to initiate Phase 3 trials for this indication, as well as a Phase 2b trial for RCC in the second quarter of 2026, with another Phase 2b clinical trial for non-IPF interstitial lung disease (non-IPF ILD)-related chronic cough planned for the second half of 2026. In October 2026, a competitor's (Nocion) Phase 2b ASPIRE study for chronic cough failed to meet its primary endpoint, which was seen as removing a potential competitor and potentially benefiting Trevi Therapeutics. Trevi Therapeutics reported a slightly wider-than-expected loss for the second quarter of 2026, with earnings per share at -$0.11, but ended the quarter with approximately $319 million in cash, cash equivalents, and marketable securities. Analysts maintain a 'Moderate Buy' consensus rating for TRVI, with price targets ranging from $23 to $40.